Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system

Arianna Bonomi, Nathalie Steimberg, Anna Benetti, Angiola Berenzi, Giulio Alessandri, Luisa Pascucci, Jennifer Boniotti, Valentina Coccè, Valeria Sordi, A. Pessina, Giovanna Mazzoleni

Research output: Contribution to journalArticle

Abstract

Multiple myeloma is an aggressive tumour able to suppress osteoblastogenesis probably mediated by bone marrow mesenchymal stromal cells (BM-MSCs) that can also support plasma cell growth/survival. The use of MSCs for multiple myeloma therapy is a controversial topic because of the contradictory results on the capacity of MSCs to inhibit or to promote cancer growth. Our previous studies demonstrated that MSCs could be loaded with Paclitaxel (PTX) and used to deliver the drug in situ in amount affecting tumour growth (in vitro and in vivo). Therefore, independently on the discussed action of MSCs in myeloma, MSCs could represent a 'trojan horse' to vehicle and deliver anti-tumour agents into bone marrow. This study confirms, by an in vitro 3D dynamic culture system, that PTX loaded BM-MSCs (PTXr-MSCs) are active on the proliferation of RPMI 8226, a human myeloma cell line. Our results demonstrated a dramatic suppression of myeloma cell growth by PTXr-MSCs, suggesting that drug loaded MSCs could be a tool to deliver drug into the bone marrow. Drug releasing MSCs provide a therapeutic approach to potentiate the existing treatments against a very aggressive malignancy as multiple myeloma.

Original languageEnglish
JournalHematological Oncology
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Paclitaxel
Multiple Myeloma
Mesenchymal Stromal Cells
Growth
Neoplasms
Pharmaceutical Preparations
Bone Marrow
Plasma Cells
Cell Survival
Cell Line
Therapeutics
In Vitro Techniques

Keywords

  • Mesenchymal stromal cells (MSCs)
  • Multiple myeloma (MM)
  • Paclitaxel
  • Rotary cell culture system (RCCS) bioreactor
  • RPMI 8226 cells

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bonomi, A., Steimberg, N., Benetti, A., Berenzi, A., Alessandri, G., Pascucci, L., ... Mazzoleni, G. (Accepted/In press). Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system. Hematological Oncology. https://doi.org/10.1002/hon.2306

Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system. / Bonomi, Arianna; Steimberg, Nathalie; Benetti, Anna; Berenzi, Angiola; Alessandri, Giulio; Pascucci, Luisa; Boniotti, Jennifer; Coccè, Valentina; Sordi, Valeria; Pessina, A.; Mazzoleni, Giovanna.

In: Hematological Oncology, 2016.

Research output: Contribution to journalArticle

Bonomi, A, Steimberg, N, Benetti, A, Berenzi, A, Alessandri, G, Pascucci, L, Boniotti, J, Coccè, V, Sordi, V, Pessina, A & Mazzoleni, G 2016, 'Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system', Hematological Oncology. https://doi.org/10.1002/hon.2306
Bonomi, Arianna ; Steimberg, Nathalie ; Benetti, Anna ; Berenzi, Angiola ; Alessandri, Giulio ; Pascucci, Luisa ; Boniotti, Jennifer ; Coccè, Valentina ; Sordi, Valeria ; Pessina, A. ; Mazzoleni, Giovanna. / Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system. In: Hematological Oncology. 2016.
@article{1e831b4e011a4ca1945b609a8374e271,
title = "Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system",
abstract = "Multiple myeloma is an aggressive tumour able to suppress osteoblastogenesis probably mediated by bone marrow mesenchymal stromal cells (BM-MSCs) that can also support plasma cell growth/survival. The use of MSCs for multiple myeloma therapy is a controversial topic because of the contradictory results on the capacity of MSCs to inhibit or to promote cancer growth. Our previous studies demonstrated that MSCs could be loaded with Paclitaxel (PTX) and used to deliver the drug in situ in amount affecting tumour growth (in vitro and in vivo). Therefore, independently on the discussed action of MSCs in myeloma, MSCs could represent a 'trojan horse' to vehicle and deliver anti-tumour agents into bone marrow. This study confirms, by an in vitro 3D dynamic culture system, that PTX loaded BM-MSCs (PTXr-MSCs) are active on the proliferation of RPMI 8226, a human myeloma cell line. Our results demonstrated a dramatic suppression of myeloma cell growth by PTXr-MSCs, suggesting that drug loaded MSCs could be a tool to deliver drug into the bone marrow. Drug releasing MSCs provide a therapeutic approach to potentiate the existing treatments against a very aggressive malignancy as multiple myeloma.",
keywords = "Mesenchymal stromal cells (MSCs), Multiple myeloma (MM), Paclitaxel, Rotary cell culture system (RCCS) bioreactor, RPMI 8226 cells",
author = "Arianna Bonomi and Nathalie Steimberg and Anna Benetti and Angiola Berenzi and Giulio Alessandri and Luisa Pascucci and Jennifer Boniotti and Valentina Cocc{\`e} and Valeria Sordi and A. Pessina and Giovanna Mazzoleni",
year = "2016",
doi = "10.1002/hon.2306",
language = "English",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",

}

TY - JOUR

T1 - Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system

AU - Bonomi, Arianna

AU - Steimberg, Nathalie

AU - Benetti, Anna

AU - Berenzi, Angiola

AU - Alessandri, Giulio

AU - Pascucci, Luisa

AU - Boniotti, Jennifer

AU - Coccè, Valentina

AU - Sordi, Valeria

AU - Pessina, A.

AU - Mazzoleni, Giovanna

PY - 2016

Y1 - 2016

N2 - Multiple myeloma is an aggressive tumour able to suppress osteoblastogenesis probably mediated by bone marrow mesenchymal stromal cells (BM-MSCs) that can also support plasma cell growth/survival. The use of MSCs for multiple myeloma therapy is a controversial topic because of the contradictory results on the capacity of MSCs to inhibit or to promote cancer growth. Our previous studies demonstrated that MSCs could be loaded with Paclitaxel (PTX) and used to deliver the drug in situ in amount affecting tumour growth (in vitro and in vivo). Therefore, independently on the discussed action of MSCs in myeloma, MSCs could represent a 'trojan horse' to vehicle and deliver anti-tumour agents into bone marrow. This study confirms, by an in vitro 3D dynamic culture system, that PTX loaded BM-MSCs (PTXr-MSCs) are active on the proliferation of RPMI 8226, a human myeloma cell line. Our results demonstrated a dramatic suppression of myeloma cell growth by PTXr-MSCs, suggesting that drug loaded MSCs could be a tool to deliver drug into the bone marrow. Drug releasing MSCs provide a therapeutic approach to potentiate the existing treatments against a very aggressive malignancy as multiple myeloma.

AB - Multiple myeloma is an aggressive tumour able to suppress osteoblastogenesis probably mediated by bone marrow mesenchymal stromal cells (BM-MSCs) that can also support plasma cell growth/survival. The use of MSCs for multiple myeloma therapy is a controversial topic because of the contradictory results on the capacity of MSCs to inhibit or to promote cancer growth. Our previous studies demonstrated that MSCs could be loaded with Paclitaxel (PTX) and used to deliver the drug in situ in amount affecting tumour growth (in vitro and in vivo). Therefore, independently on the discussed action of MSCs in myeloma, MSCs could represent a 'trojan horse' to vehicle and deliver anti-tumour agents into bone marrow. This study confirms, by an in vitro 3D dynamic culture system, that PTX loaded BM-MSCs (PTXr-MSCs) are active on the proliferation of RPMI 8226, a human myeloma cell line. Our results demonstrated a dramatic suppression of myeloma cell growth by PTXr-MSCs, suggesting that drug loaded MSCs could be a tool to deliver drug into the bone marrow. Drug releasing MSCs provide a therapeutic approach to potentiate the existing treatments against a very aggressive malignancy as multiple myeloma.

KW - Mesenchymal stromal cells (MSCs)

KW - Multiple myeloma (MM)

KW - Paclitaxel

KW - Rotary cell culture system (RCCS) bioreactor

KW - RPMI 8226 cells

UR - http://www.scopus.com/inward/record.url?scp=84977673188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977673188&partnerID=8YFLogxK

U2 - 10.1002/hon.2306

DO - 10.1002/hon.2306

M3 - Article

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

ER -